|InSite Vision Incorporated|
965 Atlantic Avenue
United States - Map
InSite Vision Incorporated, an ophthalmic product development company, engages in developing ophthalmic pharmaceutical products to address unmet eye care needs in the United States. The company develops its products based on its proprietary DuraSite drug delivery technology. It offers AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis; and Besivance, a fluoroquinolone antibiotic for the treatment of bacterial conjunctivitis. The products under development include BromSite, which has completed Phase III clinical trials for the treatment of post-operative inflammation, as well as the prevention of post-operative eye pain; DexaSite, which has completed Phase III clinical trials for the treatment of ocular inflammation; and AzaSite Plus, a fixed combination of azithromycin and dexamethasone that is in Phase III clinical trials for the treatment of ocular inflammation and infection. It is also developing DuraSite 2, a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing ophthalmic therapeutics; and ISV-101, a DuraSite formulation with low concentration of bromfenac that is used for the treatment of dry eye diseases. The company has collaborative, licensing, and service agreements with Pfizer and Pfizer Products, Inc.; Akorn, Inc.; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. InSite Vision Incorporated was founded in 1986 and is based in Alameda, California.
|Mr. Timothy Ruane M.B.A.,
Chief Exec. Officer and Director
|Mr. Louis C. Drapeau B.S., M.B.A.,
Chief Financial Officer and VP
|Mr. Surendra I. Patel ,
VP of Operations and Quality
|Dr. Kamran Hosseini M.D., Ph.D.,
Chief Medical Officer, VP of Clinical & Regulatory Affairs and Member of Scientific Advisory Board
|Dr. Lyle M. Bowman Ph.D.,
VP of Devel. and Sec.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|